Rocket Pharmaceuticals, Inc. (RCKT) stock
RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.11+0.00 (0.00%)
Close on Nov 18, 2026Market cap $231.62MP/E –Yield –
Rocket Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Rocket Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$191.64M. For fiscal 2025 it was -$231.75M. The highest annual figure on record is -$7.57M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$231.75M | – |
| FY2024 | Dec 31, 2024 | -$273.21M | – |
| FY2023 | Dec 31, 2023 | -$259.66M | – |
| FY2022 | Dec 31, 2022 | -$224.34M | – |
| FY2021 | Dec 31, 2021 | -$167.25M | – |
| FY2020 | Dec 31, 2020 | -$134.30M | – |
| FY2019 | Dec 31, 2019 | -$76.15M | – |
| FY2018 | Dec 31, 2018 | -$71.16M | – |
| FY2017 | Dec 31, 2017 | -$19.77M | – |
| FY2016 | Dec 31, 2016 | -$7.57M | – |
| FY2015 | Dec 31, 2015 | -$20.40M | – |
| FY2014 | Dec 31, 2014 | -$7.70M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$46.92M | – |
| Q1 FY2026 | Mar 31, 2026 | -$48.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$43.96M | – |
| Q3 FY2025 | Sep 30, 2025 | -$52.25M | – |
| Q2 FY2025 | Jun 30, 2025 | -$71.15M | – |
| Q1 FY2025 | Mar 31, 2025 | -$64.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$62.69M | – |
| Q3 FY2024 | Sep 30, 2024 | -$69.42M | – |
| Q2 FY2024 | Jun 30, 2024 | -$73.71M | – |
| Q1 FY2024 | Mar 31, 2024 | -$67.38M | – |
| Q4 FY2023 | Dec 31, 2023 | -$63.28M | – |
| Q3 FY2023 | Sep 30, 2023 | -$65.43M | – |
| Q2 FY2023 | Jun 30, 2023 | -$68.76M | – |
| Q1 FY2023 | Mar 31, 2023 | -$62.19M | – |
| Q4 FY2022 | Dec 31, 2022 | -$69.08M | – |
| Q3 FY2022 | Sep 30, 2022 | -$58.49M | – |
| Q2 FY2022 | Jun 30, 2022 | -$54.21M | – |
| Q1 FY2022 | Mar 31, 2022 | -$42.56M | – |
| Q4 FY2021 | Dec 31, 2021 | -$44.33M | – |
| Q3 FY2021 | Sep 30, 2021 | -$49.65M | – |
| Q2 FY2021 | Jun 30, 2021 | -$34.05M | – |
| Q1 FY2021 | Mar 31, 2021 | -$39.22M | – |
| Q4 FY2020 | Dec 31, 2020 | -$59.24M | – |
| Q3 FY2020 | Sep 30, 2020 | -$27.39M | – |
| Q2 FY2020 | Jun 30, 2020 | -$23.56M | – |
| Q1 FY2020 | Mar 31, 2020 | -$24.12M | – |
| Q4 FY2019 | Dec 31, 2019 | -$19.65M | – |
| Q3 FY2019 | Sep 30, 2019 | -$19.17M | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.39M | – |
| Q1 FY2019 | Mar 31, 2019 | -$18.95M | – |
| Q4 FY2018 | Dec 31, 2018 | -$26.55M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.33M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.87M | – |
| Q1 FY2018 | Mar 31, 2018 | -$14.41M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.66M | -130.2% |
| Q3 FY2017 | Sep 30, 2017 | -$6.73M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.52M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.87M | – |
| Q4 FY2016 | Dec 31, 2016 | $22.07M | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.72M | – |
See a number that looks wrong?